News | February 07, 2025
Merck reports 2024 sales at $64.2 billion
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Acquisition expands high-value medical platform
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Subscribe To Our Newsletter & Stay Updated
